Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1α in human glioma in vitro and in vivo

Radiotherapy and Oncology

Volumn 83, Issue 3, 2007, Pages 398-405

  Said, Harun M ^a   Hagemann, Carsten ^b   Staab, Adrian ^a   Stojic, Jelena ^b   Kühnel, Siglinde ^b   Vince, Giles H ^b   Flentje, Michael ^a   Roosen, Klaus ^b   Vordermark, Dirk ^a  

^a Department of Radiation Oncology ^*  (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

CA9; Erythropoietin; Glioma; Hypoxia; Osteopontin; VEGF

Indexed keywords

CARBONATE DEHYDRATASE IX; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OSTEOPONTIN; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CELL LINE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CARBONIC ANHYDRASES; CELL HYPOXIA; CELL LINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OSTEOPONTIN; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34250221735     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.05.003     Document Type: Article

References (30)

1. Akslen L.A., Andersen K.J., and Bjerkvig R. Characteristics of human and rat glioma cells grown in a defined medium. Anticancer Res 8 (1988) 797-803
2. Bache M., Reddemann R., Said H.M., et al. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys 66 (2006) 1481-1487
3. Bernaudin M., Marti H.H., Roussel S., et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19 (1999) 643-651
4. Brown L.F., Berse B., Van de Water L., et al. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 3 (1992) 1169-1180
5. Collingridge D.R., Piepmaier J.M., Rockwell S., and Knisely J.P. Polarographic measurement of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol 53 (1999) 127-131
6. Del Rowe J., Scott C., Werner-Wasik M., et al. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 18 (2000) 1254-1259
7. Evans SM, Judy KD, Dunphy I et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 10;8177-8184.
8. Huang L.E., Arany Z., Livingston D.M., et al. Activation of hypoxia-inducible its a transcription factor depends primarily upon redox-sensitive stabilization of subunit. J Biol Chem 271 (1996) 32253-32259
9. Kallio P.J., Pongratz I., Gradin K., et al. Activation of hypoxia-inducible factor 1a: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA 94 (1997) 5667-5672
10. Koritzinsky M., Seigneuric R., Magagnin M.G., van den Beucken T., Lambin P., and Wouters B.G. The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol 76 (2005) 177-186
11. Lal A., Petersen H., St. Croix B., et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93 (2001) 1337-1343
12. Miralbell R., Mornex F., Greiner R., et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol 17 (1999) 3143-3149
13. Potter C.P., and Harris A.L. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 89 (2003) 2-7
14. Proescholdt M.A., Mayer C., Kubitza M., et al. Expression of hypoxia-inducible carbonic anhydrases in brain tumors. Neuro-oncol 7 (2005) 465-475
15. Said H.M., Katzer A., Flentje M., and Vordermark D. Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells. Radiother Oncol 76 (2005) 200-205
16. Said H.M., Staab A., Hagemann C., et al. Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines. J Neurooncol 81 (2007) 27-38
17. Saitoh Y., Kuratsu J., Takeshima H., Yamamoto S., and Ushio Y. Expression of osteopontin in human glioma. Its correlation with malignancy. Lab Invest 72 (1995) 55-63
18. Schlaeppi J.M., and Wood J.M. Targeting vascular endothelial growth factor (VEGF) for antitumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev 18 (1999) 473-481
19. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
20. Shevde L.A., Samant R.S., Paik J.C., et al. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma MDA-MB-435. Clin Exp Metastasis 23 (2006) 123-133
21. Singers B.S., Hao J., Overgaard J., et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 76 (2005) 187-193
22. Troost E.G., Bussink J., Kaanders J.H., et al. Comparison of different methods of CA IX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol 76 (2005) 194-199
23. Vordermark D., and Brown J.M. Endogenous markers of tumor hypoxia: predictors of clinical radiation resistance?. Strahlenther Onkol 179 (2003) 801-811
24. Vordermark D., Kaffer A., Riedl S., et al. Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int J Radiat Oncol Biol Phys 61 (2005) 1197-1207
25. Vordermark D., Katzer A., Baier K., et al. Cell type-specific association of hypoxia-inducible factor-1α (HIF-1α) protein accumulation and radiobiologic tumor hypoxia. Int J Radiat Onco Biol Phys 58 (2004) 1242-1250
26. Vordermark D., Said H.M., Katzer A., et al. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 6 (2006) 207
27. Weber G.F. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552 (2001) 61-85
28. Williams K.J., Telfer B.A., Xenaki D., et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 75 (2005) 89-98
29. Yancopoulos G.D., Davis S., Gale N.W., et al. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
30. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., and Semenza G.L. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion and progression. Cancer 88 (2000) 2606-2618